KR20180045614A - Oral composition comprising policresulen - Google Patents
Oral composition comprising policresulen Download PDFInfo
- Publication number
- KR20180045614A KR20180045614A KR1020160140169A KR20160140169A KR20180045614A KR 20180045614 A KR20180045614 A KR 20180045614A KR 1020160140169 A KR1020160140169 A KR 1020160140169A KR 20160140169 A KR20160140169 A KR 20160140169A KR 20180045614 A KR20180045614 A KR 20180045614A
- Authority
- KR
- South Korea
- Prior art keywords
- oral
- sodium
- composition
- salt
- chloride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 73
- 229920001607 Policresulen Polymers 0.000 title claims abstract description 9
- ACZKMKGNTMOPBD-UHFFFAOYSA-N policresulen Chemical compound CC1=CC(O)=C(S(O)(=O)=O)C=C1CC1=CC(S(O)(=O)=O)=C(O)C(CC=2C(=CC(O)=C(C=2)S(O)(=O)=O)C)=C1C ACZKMKGNTMOPBD-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 229960002954 policresulen Drugs 0.000 title claims abstract description 8
- 210000000214 mouth Anatomy 0.000 claims abstract description 14
- 238000001179 sorption measurement Methods 0.000 claims abstract description 10
- 235000002639 sodium chloride Nutrition 0.000 claims description 42
- 150000003839 salts Chemical class 0.000 claims description 33
- 230000000694 effects Effects 0.000 claims description 30
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 21
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 21
- 241001330002 Bambuseae Species 0.000 claims description 21
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 21
- 239000011425 bamboo Substances 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 239000003212 astringent agent Substances 0.000 claims description 15
- 230000001965 increasing effect Effects 0.000 claims description 13
- 230000002708 enhancing effect Effects 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 5
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- 235000011148 calcium chloride Nutrition 0.000 claims description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 3
- 235000011147 magnesium chloride Nutrition 0.000 claims description 3
- 239000001103 potassium chloride Substances 0.000 claims description 3
- 235000011164 potassium chloride Nutrition 0.000 claims description 3
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 claims description 3
- 229910052939 potassium sulfate Inorganic materials 0.000 claims description 3
- 235000011151 potassium sulphates Nutrition 0.000 claims description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 4
- 229910000397 disodium phosphate Inorganic materials 0.000 claims 4
- 235000019800 disodium phosphate Nutrition 0.000 claims 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 abstract description 5
- 201000001245 periodontitis Diseases 0.000 abstract description 4
- 230000007505 plaque formation Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000606 toothpaste Substances 0.000 description 23
- 229940034610 toothpaste Drugs 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 20
- 230000000052 comparative effect Effects 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- -1 sulfate compound Chemical class 0.000 description 7
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000000080 wetting agent Substances 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000004088 foaming agent Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 239000003765 sweetening agent Substances 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 230000001680 brushing effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004376 Sucralose Substances 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000032770 biofilm formation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003749 cleanliness Effects 0.000 description 3
- 239000000551 dentifrice Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011775 sodium fluoride Substances 0.000 description 3
- 235000013024 sodium fluoride Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019408 sucralose Nutrition 0.000 description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- ZZPQSQFQHIGCRC-OOFFSTKBSA-N (2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound [Zn].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ZZPQSQFQHIGCRC-OOFFSTKBSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- KWSLGOVYXMQPPX-UHFFFAOYSA-N 5-[3-(trifluoromethyl)phenyl]-2h-tetrazole Chemical compound FC(F)(F)C1=CC=CC(C2=NNN=N2)=C1 KWSLGOVYXMQPPX-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 244000059266 Piper nigrescens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000388 Polyphosphate Polymers 0.000 description 1
- 241001135225 Prevotella nigrescens Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- WUKWITHWXAAZEY-UHFFFAOYSA-L calcium difluoride Chemical compound [F-].[F-].[Ca+2] WUKWITHWXAAZEY-UHFFFAOYSA-L 0.000 description 1
- 229910001634 calcium fluoride Inorganic materials 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- MDQRDWAGHRLBPA-UHFFFAOYSA-N fluoroamine Chemical compound FN MDQRDWAGHRLBPA-UHFFFAOYSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 150000002366 halogen compounds Chemical class 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940042125 oral ointment Drugs 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000001205 polyphosphate Substances 0.000 description 1
- 235000011176 polyphosphates Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- BFDWBSRJQZPEEB-UHFFFAOYSA-L sodium fluorophosphate Chemical compound [Na+].[Na+].[O-]P([O-])(F)=O BFDWBSRJQZPEEB-UHFFFAOYSA-L 0.000 description 1
- 229910001379 sodium hypophosphite Inorganic materials 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical compound [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940041603 vitamin k 3 Drugs 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y10S514/8995—
-
- Y10S514/90—
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 폴리크레줄렌을 포함하는 구강용 조성물에 관한 것이다. 보다 구체적으로 폴리크레줄렌의 치태형성 방지 효과, 및 치주염과 치은염의 완화 효과가 더욱 개선된 구강용, 특히 구강 위생 증진용 조성물에 관한 것이다.The present invention relates to an oral composition comprising polycrystalline. More specifically, the present invention relates to a composition for preventing or preventing plaque formation of polycrysulene, and a composition for promoting oral hygiene, wherein the effect of reducing periodontitis and gingivitis is further improved.
구강 내에서 구강균에 의해 형성되는 프라그는 충치, 치은염 등 구강 관련 질환의 1차적 원인이라 할 수 있다. The plaque formed by oral bacteria in the oral cavity is the primary cause of oral-related diseases such as tooth decay and gingivitis.
대한민국 공개특허공보 10-2015-0066756호에서는 폴리크레줄렌이 포함된 바이오필름 형성 억제용 조성물을 통해 폴리크레줄렌을 구강 내에 적용함으로써 생물막 또는 균막이라 불리는 바이오필름의 형성을 억제할 수 있고, 이를 통하여 정상적인 세균의 생태계를 파괴하지 않고도 구강 내에서 프라그 형성을 억제할 수 있음을 개시하고 있다.In Korean Patent Laid-Open Publication No. 10-2015-0066756, it is possible to inhibit the formation of a biofilm called biofilm or membrane by applying polycrylene into the oral cavity through a composition for inhibiting biofilm formation containing polycrystalline, It is possible to inhibit plaque formation in the oral cavity without destroying normal bacteriological ecosystems.
그러나, 본 발명자들의 연구 결과 폴리크레줄렌이 함유된 구강용 조성물의 경우 그 효과가 오랫동안 지속되지 않음이 밝혀졌고, 따라서 이러한 효과의 지속을 위한 연구가 필요하게 되었다. However, the inventors of the present invention have found that the effect of the oral composition containing polycrysulene is not maintained for a long period of time, and therefore, research for continuing this effect is required.
따라서 본 발명이 해결하고자 하는 과제는 효과의 지속시간이 늘어나거나(늘어나고) 효과가 향상된 폴리크레줄렌 함유 구강용 조성물, 특히 구강 위생용 조성물을 제공하는 것이다.Accordingly, a problem to be solved by the present invention is to provide a composition for oral care containing polycrysulene, in particular, a composition for oral hygiene which has an increased duration (or increased effect) of effect.
본 발명이 해결하고자 하는 다른 과제는 폴리크레줄렌의 효과 지속시간을 늘리거나(늘리고) 폴리크레줄렌의 효과를 향상시키기 위한 방법을 제공하는 것이다. Another object to be solved by the present invention is to provide a method for increasing (or increasing) the duration of effect of polycrysulene and improving the effect of polycrysulene.
본 발명이 해결하고자 하는 또 다른 과제는 폴리크레줄렌의 효과 지속시간을 늘리거나(늘리고) 폴리크레줄렌의 효과를 향상시킬 수 있는 조성물 및/또는 이러한 조성물을 포함하는 키트를 제공하는 것이다. Another object to be solved by the present invention is to provide a composition and / or a kit containing such a composition that can increase (or increase) the duration of effect of polycrysulene and improve the effect of polycrysulene.
상기 과제를 해결하기 위하여, 본 발명은 구강조직수렴제를 이용하여 폴리크레줄렌(policresulen)의 효과 지속시간을 늘리거나(늘리고) 효과를 향상시킬 수 있다는 기술사상을 제공한다.In order to solve the above-described problems, the present invention provides a technical idea that the effect duration of a policresulen can be increased or increased by using an oral tissue astringent agent.
먼저 본 발명자들의 연구 결과 구강 내 환경의 특성상 수용성 물질인 폴리크레줄렌이 구강 내에서 오래 머무르기 어려워 폴리크레줄렌이 구강 내에서 지속적으로 효과를 발휘하기 어렵다는 점을 확인하였고, 따라서 구강 점막 또는 잇몸에서 잔류하면서 폴리크레줄렌이 약리작용을 지속적으로 유지할 수 있도록 하는 기술을 필요로 하게 되었다. 본 발명자들은 상기와 같은 종래 기술에서의 문제점을 해결하기 위해 다양한 연구를 수행하던 중 폴리크레줄렌을 함유하는 조성물에 구강조직수렴제를 포함시킬 경우 폴리크레줄렌의 구강 내 흡착을 향상시키고, 지속적으로 바이오필름 생성을 억제하는 우수한 효과가 있음을 확인하여 본 발명을 완성하게 되었다. 다만, 본 발명은 이러한 기전적 추측에 한정되는 것은 아니다. As a result of the study by the inventors of the present invention, it was confirmed that polycrysulene, which is a water-soluble substance, is hard to stay in the mouth for a long time due to the characteristics of the oral cavity environment and thus it is difficult for the polycrysulene to continuously exhibit its effects in the oral cavity. And the need for a technique to keep the pharmacological action of polycrysulene constant. DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention The present inventors have conducted various studies to solve the problems in the prior art as described above. When the oral tissue astringent is included in a composition containing polycrystalline, the inventors have improved the adsorption of polycrystalline in the oral cavity, It was found that there was an excellent effect of inhibiting film formation, and thus the present invention was completed. However, the present invention is not limited to these conventional guesses.
따라서 본 발명은 (a) 폴리크레줄렌(policresulen) 및 (b) 구강조직수렴제를 포함하는 구강용 조성물, 특히 구강 위생 증진용 조성물을 제공한다.Accordingly, the present invention provides an oral composition, particularly a composition for enhancing oral hygiene, comprising (a) policresulen and (b) an oral tissue astringent.
본 발명은 또한 폴리크레줄렌을 함유하는 구강용 조성물에 있어서, 폴리크레줄렌의 효과를 높이기 위한 용도로 구강조직수렴제를 포함하는 것을 특징으로 하는 구강용, 특히 구강 위생 증진용 조성물을 제공한다.The present invention also provides a composition for oral administration, particularly a composition for enhancing oral hygiene, which comprises an oral tissue astringent agent as an application for enhancing the effect of polycrysulene in an oral composition containing polycrysulene.
본 발명은 또한 구강조직수렴제를 폴리크레줄렌의 적용과 동시에 또는 폴리크레줄렌의 적용 전에 구강 내에 적용하는 것을 특징으로 하는 폴리크레줄렌의 효과를 높이기 위한 방법을 제공한다. 이러한 방법을 통해 구강 내 위생을 더욱 증진할 수 있다. The present invention also provides a method for enhancing the effect of polycrystalline, characterized in that the oral tissue astringent is applied in the mouth concurrently with the application of polycrystalline or prior to application of polycrystalline. In this way, oral hygiene can be further enhanced.
본 발명은 또한 (a) 폴리크레줄렌을 함유하는 조성물, 및 (b) 상기 폴리크레줄렌의 효과를 높이기 위한 용도의 구강조직수렴제를 포함하는 조성물을 포함하는 구강용 키트를 제공한다.The present invention also provides an oral kit comprising a composition comprising (a) a composition comprising polycrystalline, and (b) an oral tissue astringent for use to enhance the effect of the polycrystalline.
본 발명은 또한 구강조직수렴제를 유효성분으로 포함하는, 폴리크레줄렌의 효과 증진용 조성물을 제공한다.The present invention also provides a composition for enhancing the effect of polycrystalline comprising an oral tissue astringent as an active ingredient.
본 발명에서 '구강용 조성물' 또는 '구강 위생용 조성물'은 바이오필름의 형성 억제를 통하여 치태형성 방지 및/또는 구강 위생 증진 및/또는 치주염, 치은염과 같은 구강 질환의 예방 및/또는 치료 효과를 갖는 구강에의 적용을 위한 조성물을 의미할 수 있으며, 폴리크레줄렌을 효력증진물질인 구강조직수렴제를 함께 포함함으로써 폴리크레줄렌의 구강 내 잔류 및/또는 흡착이 높아져서 보다 우수한 바이오필름형성 억제를 통하여 상기 목적하는 효과를 더욱 우수하게 발휘할 수 있다.The 'oral composition' or 'oral hygiene composition' according to the present invention can prevent the formation of teeth and / or promote oral hygiene and / or prevent and / or treat oral diseases such as periodontitis and gingivitis through inhibition of biofilm formation The present invention also relates to a composition for oral application of polycrysulene, which comprises polycrysulene as an effective enhancing substance, together with an oral tissue astringent, to increase the residual and / or adsorption of polycrystalline in the oral cavity, The desired effect can be exerted more excellently.
본 발명에 사용되는 폴리크레줄렌(Policresulene)은 알보칠(Albothyl) 또는 폴리렌(Polilen)으로 불리기도 하며, 하기 화학식 1의 구조를 가지며, 화학식은 (C9H8O4S)n과 같다. Policresulene used in the present invention may also be referred to as Albothyl or Polylene and has a structure of the following
바람직하게, 상기 화학식 1에서 n은 1 내지 3이며, 더욱 바람직하게 n은 3이다.Preferably, n in the general formula (1) is 1 to 3, more preferably n is 3.
본 발명의 폴리크레줄렌은 물에 잘 녹기 때문에 물이 과량 함유되어 있는 치약과 같은 구강용 조성물 내에 석출되지 않고 용해되어 존재하게 된다.Since the polycrysulene of the present invention is well soluble in water, it is dissolved and present in an oral composition such as a toothpaste containing an excessive amount of water without precipitation.
본 발명에 있어 상기 구강조직수렴제를 폴리크레줄렌의 잔류 및/또는 흡착을 높이는 역할을 함은 분명하나, 이러한 역할 이외에 다른 추가적인 역할을 할 수 있으며, 본 발명은 구강조직수렴제가 작용하는 폴리크레줄렌의 잔류 및/또는 흡착 증진이라는 특별한 이론적 기전에 한정되는 것은 아니다. In the present invention, it is obvious that the oral tissue astringent agent plays a role of enhancing the residual and / or adsorption of polycrystalline, but it may play an additional role in addition to this role. In the present invention, But is not limited to a particular theoretical mechanism of the retention and / or adsorption enhancement.
본 발명의 구강조직수렴제는 나트륨, 칼륨, 칼슘, 및 마그네슘과 같이 양이온을 함유한 할로겐족화합물, 설페이트 화합물, 카보네이트 화합물, 인산염화합물 또는 이의 혼합물들이 사용될 수 있다. The oral tissue astringent of the present invention may be a halogen compound containing a cation such as sodium, potassium, calcium, and magnesium, a sulfate compound, a carbonate compound, a phosphate compound, or a mixture thereof.
구체적으로, 상기 구강조직수렴제는 염화나트륨, 염화칼륨, 염화칼슘, 염화마그네슘, 황산나트륨, 황산칼륨, 탄산수소나트륨, 탄산나트륨, 제1인산칼륨, 제2인산칼륨, 제3인산칼륨, 제1인산나트륨, 제2인산나트륨, 제3인산나트륨, 및 사카린나트륨으로 이루어진 군으로부터 선택된 1종 이상일 수 있다. Specifically, the oral tissue astringent may be selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, magnesium chloride, sodium sulfate, potassium sulfate, sodium hydrogen carbonate, sodium carbonate, potassium phosphate monobasic, potassium phosphate dibasic, At least one selected from the group consisting of sodium phosphate, sodium tertiary phosphate, and sodium saccharin.
상기 염화나트륨은 염화나트륨을 포함하는 소금의 형태로 포함될 수 있고, 예컨대, 죽염, 자죽염, 천일염, 정제소금, 제제소금, 또는 약전소금 등의 형태로 포함될 수 있으며, 바람직하게는 죽염의 형태로 포함될 수 있다. The sodium chloride may be contained in the form of salt containing sodium chloride and may be contained in the form of, for example, bamboo salt, bamboo salt, sun salt, refined salt, formulated salt or pharmacopoeial salt, have.
여러 구강조직수렴제들 중에서 특히 죽염의 형태가 실제 사용시 세정감, 깔끔함의 지속, 향미, 전반적인 만족도 등의 측면에서 더욱 바람직하다.Among the various oral tissue astringents, the form of bamboo salt is more preferable in terms of the feeling of touch, the continuity of cleanliness, flavor and overall satisfaction in actual use.
본 발명에서 사용하는 염화나트륨 중 죽염은 대나무를 사용한 소금의 총칭으로, 예컨대, 대한민국 특허등록 제85705호에서 언급한 대나무와 소금을 사용하여 화법(火法)을 통해 합성한 죽염이고, 이는 세포를 생성시키는 세포 생산작용을 하는 대나무와 살균 및 부패를 방지하는 소금을 소성로에서 고열로 여러 번 반복 처리하여 소금을 용융시키고, 굳히는 방법으로 죽염을 만들고 있다. 이렇게 제조된 죽염은 나트륨 이외에도 칼륨, 칼슘, 마그네슘, 철 등의 미네랄 성분들이 많이 함유되어 있다. 자죽염의 경우에도 죽염과 유사한 함량의 미네랄 및 이온 성분을 함유하고 있다. 죽염 또는 자죽염에 함유되어 있는 여러 종류의 미네랄 성분과 염화나트륨 성분에 의하여 양치 시 구강 점막의 수렴작용이 특히 탁월하다. 수렴이 발생하면서 팽창되어 있는 세포들이 수축되게 되고 이때 구강 점막에 있던 폴리크레줄렌이 구강 조직에 수렴하게 되며 이로써 잔류하는 폴리크레줄렌이 지속적으로 약효성을 발휘하게 되는 것으로 추측된다. 다만, 본 발명은 이러한 이론적 기전에 한정되는 것은 아니다.Bamboo salt in sodium chloride used in the present invention is a generic name of salt using bamboo, and is, for example, bamboo salt synthesized through a pyrogen method using bamboo and salt mentioned in Korean Patent Registration No. 85705, Bamboo, a cell-producing bamboo, and salt that prevents sterilization and decay are repeated several times from a baking furnace to a high temperature to melt salt, and to make bamboo salt by hardening. The bamboo salt thus produced contains a lot of minerals such as potassium, calcium, magnesium and iron in addition to sodium. Bamboo salt also contains similar mineral and ionic components to bamboo salt. It is especially excellent for the oral mucous membrane to converge when it is applied by various kinds of minerals and sodium chloride components contained in bamboo salt or bamboo salt. As the convergence occurs, the swollen cells are contracted. At this time, the polycrysulene in the buccal mucosa converges on the oral tissues, and it is presumed that the remaining polycrysulene continuously exhibits the weak efficacy. However, the present invention is not limited to this theoretical mechanism.
본 발명에 따른 구강용 조성물 또는 구강 내 폴리크레줄렌 잔류 또는 흡착 증진용 조성물에 있어 폴리크레줄렌의 함량은 본 발명의 여러 목적상 조성물 총 중량 대비 0.0005 내지 2 중량%가 바람직하며, 0.0001 내지 1 중량%가 보다 바람직하고, 0.001 내지 0.1 중량%가 더욱 더 바람직하다. 또한 본 발명에 따른 조성물에 있어 구강조직수렴제의 함량은 본 발명의 여러 목적상 0.1 내지 5 중량%가 바람직하며, 0.2 내지 4 중량%가 더욱 바람직하고, 0.3 내지 3 중량%가 더욱 더 바람직하다. The content of polycrystalline in the composition for oral cavity or intraocular polycarzulene residue or adsorption enhancement according to the present invention is preferably 0.0005 to 2% by weight, more preferably 0.0001 to 1% by weight based on the total weight of the composition for various purposes of the present invention %, And still more preferably 0.001 to 0.1 wt%. In addition, the content of the oral tissue astringent agent in the composition according to the present invention is preferably 0.1 to 5% by weight, more preferably 0.2 to 4% by weight, and still more preferably 0.3 to 3% by weight for various purposes of the present invention.
상기 폴리크레줄렌의 함량은 조성물 총 중량 대비 0.0005 중량% 미만일 때는 바이오필름 생성 억제 효과가 미미하여 본 발명의 실질적 목적을 달성하기 쉽지 않았으며, 2 중량% 초과일 때는 자극 및 외과적 상처를 일으킬 수 있다는 문제점이 있다.When the content of the polycrysulene is less than 0.0005% by weight based on the total weight of the composition, the effect of inhibiting the biofilm formation is small and it is difficult to achieve the practical purpose of the present invention. If the content exceeds 2% by weight, stimulation and surgical wound There is a problem.
상기 구강조직수렴제는 폴리크레줄렌의 흡착 및 잔류 효과의 상승 등 본 발명의 목적을 위해 첨가하는 것으로, 그 함량이 조성물 총 중량 대비 0.1 중량% 미만이면 구강 내 흡착 및 잔류 효과가 미약하게 되고, 5 중량%를 초과하면 함량 증가에 따른 효과가 미미할 뿐만 아니라 염의 과량 첨가로 인해 짠맛, 비린맛, 떫은 맛 등이 강하게 나타날 수 있다. 본 발명자들이 남녀 10여명을 대상으로 수행한 관능평가 결과 5 중량%를 초과하는 경우 소비자 선호도가 매우 떨어지는 결과를 나타내었다. The oral tissue astringent agent is added for the purpose of the present invention such as increase in adsorption and residual effect of polycrystalline. When the content is less than 0.1% by weight based on the total weight of the composition, If the content is more than 10% by weight, the effect of increasing the content is insignificant. In addition, excessive salt addition may result in strong salty, pungent, and pungent taste. As a result of the sensory evaluation performed by the present inventors on about 10 men and women, when the content exceeded 5% by weight, consumer preference was very poor.
본 발명의 조성물은 치약, 구강 청정제, 양치액, 구강 스프레이, 껌, 구강 연고, 구강용 패취제 등 다양한 형태로 제공될 수 있다. 상기 조성물의 형태, 종류 및 사용 목적에 따라 통상적으로 연마제, 습윤제, 결합제, 기포제, 감미제, 방부제, 약효제, 향료, 산성도 조절제, 증백제 등을 적당량 배합하여 사용할 수 있다. 즉, 본 발명에 따른 조성물은 앞서 언급된 성분들 이외에 또한 구강용 조성물에 적절한 제형화, 제형 안정성, 소망하는 효과의 증진, 사용 기호도 증진 등을 위하여, 연마제, 습윤제, 결합제, 기포제, 감미제, 약효제, 향료, 정제수 등으로 이루어진 군에서 선택된 1종 이상의 첨가제를 추가로 함유할 수 있다.The composition of the present invention may be provided in various forms such as toothpaste, mouthwash, mouthwash, oral spray, gum, oral ointment, oral patch, and the like. A wetting agent, a binder, a foaming agent, a sweetener, a preservative, a medicinal agent, a flavoring agent, an acidity regulating agent and a brightener may be appropriately used depending on the type, the kind and the purpose of use of the composition. That is, in addition to the above-mentioned components, the composition according to the present invention may further contain various additives such as an abrasive, a wetting agent, a binder, a foaming agent, a sweetening agent, a drug efficacy, and the like for the purpose of appropriate formulation, formulation stability, A flavoring agent, a purified water, and the like.
본 발명의 구강 위생 증진용 조성물 또는 구강 내 폴리크레줄렌 잔류/흡착 증진용 조성물을 포함하는 제형이 치약 조성물인 경우, 연마제, 습윤제, 결합제, 기포제, 감미제, 약효제, 향료, 산성도 조절제 및 증백제로 이루어진 군으로부터 선택된 1종 이상의 첨가제를 더욱 포함할 수 있다.When the formulation comprising the composition for promoting oral hygiene of the present invention or the composition for retaining / enhancing the intraocular polycrylaine is a dentifrice composition, it is preferable that the composition is an abrasive, a wetting agent, a binder, a foaming agent, a sweetener, a medicinal agent, a flavoring agent, And at least one additive selected from the group consisting of:
상기 연마제는 인산일수소칼슘, 침강실리카, 탄산칼슘, 함수알루미나, 카오린 및 중조로 이루어진 군으로부터 선택된 1종 이상, 바람직하게는 인산일수소칼슘 및/또는 침강실리카이고, 조성물 총 중량 대비 5 내지 50 중량%로 사용할 수 있다.The abrasive is at least one selected from the group consisting of calcium monohydrogenphosphate, precipitated silica, calcium carbonate, hydrated alumina, kaolin and sodium hypophosphite, preferably calcium monohydrogenphosphate and / or precipitated silica, % ≪ / RTI > by weight.
상기 습윤제로는 글리세린, 소르비톨, 비결정성 소르비톨액, 프로필렌글리콜, 폴리에틸렌 글리콜 및 자일리톨로 이루어진 군으로부터 선택된 1 종 이상, 바람직하게는 소르비톨액이고, 예를 들어, 조성물 총 중량 대비 20 내지 60 중량%로 사용할 수 있다.The wetting agent is preferably at least one selected from the group consisting of glycerin, sorbitol, amorphous sorbitol solution, propylene glycol, polyethylene glycol and xylitol, preferably a sorbitol solution, for example 20 to 60 wt% Can be used.
상기 결합제로는 카르복시메틸셀룰로오스나트륨, 카라기난, 잔탄검, 히드록시에틸셀룰로오스, 히드록시프로필메틸셀룰로오스, 히드록시프로필셀룰로오스, 구아검, 젤란검, 카르보머, 펙틴, 폴리비닐피롤리돈, 카르복시비닐폴리며, 알긴산나트륨 및 라포나이트로 이루어진 군으로부터 선택된 1종 이상, 바람직하게는 카르복시메틸셀룰로오스나트륨이고, 예를 들어, 조성물 총 중량 대비 0.5 내지 2 중량%로 사용할 수 있다.Examples of the binder include sodium carboxymethylcellulose, carrageenan, xanthan gum, hydroxyethylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, guar gum, gellan gum, carbomer, pectin, polyvinylpyrrolidone, carboxyvinylpoly And at least one selected from the group consisting of sodium alginate and laponite, preferably carboxymethyl cellulose sodium, and may be used, for example, in an amount of 0.5 to 2% by weight based on the total weight of the composition.
상기 기포제로는 라우릴황산나트륨, 라우릴사르코신산나트륨 등의 음이온계면활성제; 소르비탄 지방산에스테르, 폴리옥시에틸렌경화피마자유, 폴리옥시에틸렌/폴리옥시프로필렌계 공중합 물질 등으로 이루어진 비이온계면활성제; 또는 코코아이도프로필베타인 등의 양쪽성 계면활성제로부터 선택된 1종 이상, 바람직하게는 라우릴황산나트륨이고, 조성물 총 중량 대비 0.5 내지 5 중량%로 사용할 수 있다.Examples of the foaming agent include anionic surfactants such as sodium lauryl sulfate and sodium lauryl sarcosinate; Sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, polyoxyethylene / polyoxypropylene type copolymer materials and the like; Or an amphoteric surfactant such as cocoa idopropylbetaine, preferably sodium lauryl sulfate, and may be used in an amount of 0.5 to 5% by weight based on the total weight of the composition.
상기 감미제는 수크랄로스, 말티톨, 아스파탐, 에리스리톨 및 감초산으로 이루어진 군으로부터 선택된 1종 또는 2종 이상, 바람직하게는 수크랄로스이고, 조성물 총 중량 대비 0.05 내지 0.3 중량%로 사용할 수 있다.The sweetener may be one or two or more, preferably sucralose, selected from the group consisting of sucralose, maltitol, aspartame, erythritol and licorice acid, and may be used in an amount of 0.05 to 0.3% by weight based on the total weight of the composition.
상기 약효제로는 불화나트륨, 불화인산나트륨, 불화제일석, 불화아민, 클로르헥시딘, 아미노카프로산, 글리시리진산디칼륨, 트라넥사민산, 알로토인류, 카프론산류, 폴리인산염류, 효소류 및 생약추출물로 이루어진 군으로부터 선택된 1종 이상, 바람직하게는 불화나트륨이고, 조성물 총 중량 대비 0.1 내지 0.3 중량%로 사용할 수 있다.Examples of the active agent include sodium fluoride, sodium fluorophosphate, calcium fluoride, fluoroamine, chlorhexidine, aminocaproic acid, dipotassium glycyrrhizinate, tranexamic acid, allantoin, caproic acids, polyphosphates, , Preferably sodium fluoride, 0.1 to 0.3% by weight based on the total weight of the composition.
상기 향료로는 페퍼민트오일, 스피어민트오일 등의 천연 향료와 멘톨, 카르본 등의 합성착향료를 적당량 혼합하여 사용하며, 바람직하게는 이들을 일정 비율 혼합한 향료에 아니스 오일을 적당량 혼합하는 것이 좋다. 향료의 함량은 조성물 총 중량 대비 0.5 내지 3중량%로 사용할 수 있다.As the fragrance, an appropriate amount of synthetic flavoring agents such as peppermint oil, spearmint oil and the like and a synthetic flavoring agent such as menthol and carboin are mixed and used. Preferably, an appropriate amount of anise oil is mixed with a certain amount of the fragrance. The content of the perfume may be 0.5 to 3% by weight based on the total weight of the composition.
예컨대, 상기 구강용 위생용 조성물 또는 구강 내 폴리크레줄렌 흡착 증진용 조성물은 조성물 총 중량 대비 폴리크레줄렌 0.0005 내지 2 중량% 및 염화나트륨 0.1 내지 5 중량%를 포함하고, 첨가제로서 연마제 15 내지 60 중량%, 습윤제 20 내지 60 중량%, 결합제 0.5 내지 20 중량%, 기포제 0.5 내지 5 중량%, 감미제 0.05 내지 0.3 중량%, 약효제 0.1 내지 0.3 중량%, 향료 0.5 내지 3 중량% 및 잔량의 정제수를 포함하는 것일 수 있다.For example, the composition for oral hygiene or intraoral oral adsorption enhancer comprises 0.0005 to 2% by weight of polycrystalline and 0.1 to 5% by weight of sodium chloride relative to the total weight of the composition, 15 to 60% by weight of an abrasive as an additive, By weight of a sweetener, 0.1 to 0.3% by weight of a pharmacologically active agent, 0.5 to 3% by weight of a flavoring agent, and a balance of purified water, wherein the wetting agent comprises 20 to 60% by weight of a wetting agent, 0.5 to 20% by weight of a binder, 0.5 to 5% Lt; / RTI >
본 발명은 효과의 지속시간이 늘어나거나(늘어나고) 효과가 향상된 폴리크레줄렌 함유 구강용 조성물, 특히 구강 위생용 조성물을 제공한다. The present invention provides a composition for oral care containing polycrysulene, particularly a composition for oral hygiene, which has an increased duration (or increased effect) of effect.
본 발명은 또한 폴리크레줄렌의 효과 지속시간을 늘리거나(늘리고) 폴리크레줄렌의 효과를 향상시키기 위한 방법을 제공한다. The present invention also provides a method for increasing (or increasing) duration of effect of polycrysulene and improving the effect of polycrysulene.
본 발명은 또한 폴리크레줄렌의 효과 지속시간을 늘리거나(늘리고) 폴리크레줄렌의 효과를 향상시킬 수 있는 조성물 및/또는 이러한 조성물을 포함하는 키트를 제공한다. The present invention also provides compositions and / or kits comprising such compositions that can increase (or increase) the duration of effect of polycrysulene and enhance the effect of polycrysulene.
결과적으로 본 발명에 따른 조성물은 폴리크레줄렌의 구강 내 잔류력을 향상시키고, 치태형성 방지 효과, 및 치주염, 치은염의 염증 완화 효과가 우수하다. As a result, the composition according to the present invention improves the residual force in oral cavity of polycrysulene, has an effect of preventing plaque formation, and has an effect of reducing inflammation of periodontitis and gingivitis.
도 1은 실험예 2의 결과물들의 평점에 사용된 플라크 지표(index)를 보여주는 도면이다. 당업계에서 통상적으로 사용되는 "Turesky Modification of Quigley-Hein plaque index"를 사용하였다.
도 2는 본 발명에 따른 일 실시예들인 치약들의 소비자 평가에서 사용한 설문지를 나타낸다.
도 3은 본 발명에 따른 일 실시예들인 치약들의 소비자 평가 결과이다.FIG. 1 is a diagram showing a plaque index used in the evaluation of the results of Experimental Example 2. FIG. Quot; Turesky Modification of Quigley-Hein plaque index "which is commonly used in the art.
2 shows a questionnaire used in a consumer evaluation of toothpastes according to one embodiment of the present invention.
Figure 3 is a consumer assessment of toothpaste embodiments in accordance with the present invention.
이하, 본 발명의 이해를 돕기 위하여 실시예 등을 들어 상세하게 설명하기로 한다. 그러나, 본 발명에 따른 실시예들은 여러 가지 다른 형태로 변형될 수 있으며, 본 발명의 범위가 하기 실시예들에 한정되는 것으로 해석되어서는 안 된다. 본 발명의 실시예들은 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, embodiments of the present invention will be described in detail to facilitate understanding of the present invention. However, the embodiments according to the present invention can be modified into various other forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the invention are provided to more fully describe the present invention to those skilled in the art.
실시예Example 1 내지 11 및 1 to 11 and 비교예Comparative Example 1 내지 3 1 to 3
실시예 1 내지 11 및 비교예 1 내지 3의 치약 조성물은 하기 표 1에 나타낸 성분 및 조성비로 제조하였다. 습윤 성분인 솔르비톨액에 카르복시 메틸셀룰로오스나트륨, 등의 분말 성분을 분산시키고 정제수를 넣은 다음 혼합기에서 1차 혼합하였다. 그 다음에 침강 실리카 등의 연마제와 약효제를 투입하고 혼합하였다.The dentifrice compositions of Examples 1 to 11 and Comparative Examples 1 to 3 were prepared with the components and composition ratios shown in Table 1 below. Powder components such as carboxymethylcellulose sodium and the like were dispersed in Solvitol solution, which is a wetting component, and purified water was added, followed by primary mixing in a mixer. Then, an abrasive such as precipitated silica and a pharmaceutical agent were added and mixed.
마지막으로 기포제인 라우릴 황산나트륨 및 향료성분을 넣고 진공상태하에서 혼합하여 치약 조성물을 제조하였다.Finally, sodium lauryl sulfate as a foaming agent and fragrance components were added and mixed under vacuum to prepare a dentifrice composition.
(단위: 중량%)division
(Unit: wt%)
(70%)Sorbitol solution
(70%)
실험예 1. 폴리크레줄렌의 검출 유무 측정Experimental Example 1. Measurement of presence or absence of polycrystalline
상기 표 1의 실시예 및 비교예의 조성물을 20~40대 남여 소비자 10명을 대상으로 양치를 1분간 하게 한 후, 타액을 시간 경과에 따라 타액을 채취하여 폴리크레줄렌의 검출 유무를 액체크로마토그래프법을 이용하여 측정하였다.After brushing for 10 minutes, the saliva was collected over a period of 1 minute, and the presence or absence of the detection of polycrystalline was measured with a liquid chromatograph Method.
측정 결과는 하기 표 2에서 폴리크레줄렌의 검출 또는 불검출(검출(O), 불검출(X))로만 표기하였다.The measurement results are shown in Table 2 only as detection or non-detection (detection (O), non-detection (X)) of polycrystalline.
상기 표 2에서 나타나는 바와 같이, 실험결과 실시예에서는 폴리크레줄렌이 양치 후 30분까지 지속적으로 검출되는 것을 확인하였으나, 비교예 2의 치약은 양치 직후에는 검출이 되었으나, 타액에 의한 희석 및 섭취로 인하여 양치 직후인 5분 후에도 검출되지 않는 것이 확인되었다. 즉 구강조직수렴제와 동시에 사용하여 줌으로써 폴리크레줄렌의 잔류력이 현격하게 증가하였음을 확인할 수 있었다.As shown in the above Table 2, in the experimental results, it was confirmed that the polycrysulene was continuously detected until 30 minutes after brushing, but the toothpaste of Comparative Example 2 was detected immediately after brushing, but dilution and ingestion by saliva It was not detected even after 5 minutes immediately after brushing. That is, it was confirmed that the residual force of polycrysulene was significantly increased by the simultaneous use with the oral tissue astringent agent.
실험예Experimental Example 2. 2. 폴리크레줄렌Polycrystalline 및 죽염 함유치약의 And bamboo salt-containing toothpaste 치면세균막형성Tooth film formation 억제 효과 Inhibitory effect
<실험 방법><Experimental Method>
현존 자연치아 수가 최소 20개 이상인 만 20-65세 성인 남녀를 대상으로 상기 표 1의 실시예 2 및 비교예 1 내지 2를 4주간 사용하게 한 뒤 초기 및 4주 후에 다음 방식으로 치면 세균막 지수를 점수로 평가하였다. 연구 대상자 구강 내 존재하는 20개 이상의 모든 자연치를 대상으로 한 치아를 6개 면(협측-근심, 협측-중앙, 협측-원심, 설측-근심, 설측-중앙, 설측-원심)으로 나누어 평가하였다. 이 때, 고정성 교정 장치가 장착되어 있거나 전체 치면을 수복한 치관은 제외하였다. 치면세균막 형성억제를 평가하기 위한 지수 평가는 치태 염색 시약을 이용하여 치태를 염색한 후, Turesky Modification of Quigley-Hein plaque index (PI)를 도 1 및 다음과 같은 기준에 의하여 1인 검사자가 평점하였다. In the case of men and women aged 20 to 65 years who have at least 20 natural teeth, using Example 2 and Comparative Examples 1 and 2 of Table 1 for 4 weeks, after the initial and 4 weeks, . The subjects were divided into six groups (buccal, medial, buccal, medial, buccal, lingual, lingual, lingual, lingual). At this time, the crown with a fixed orthodontic appliance or with a complete restoration of the tooth surface was excluded. In order to evaluate the inhibition of bacterial membrane formation, dental plaques were stained using a dental staining reagent, and then one of the testers was evaluated by the Turesky Modification of Quigley-Hein plaque index (PI) according to the following criteria .
0점 = 전혀 치태가 없는 경우 0 point = no plaque at all
1점 = 치태가 연결되지 않고 한 개의 섬 형태를 지닐 경우1 point = When the teeth are not connected and have one island shape
2점 = 치은변연을 따라 선의 형태로 치태가 있는 경우 2 points = When there is a plaque in the form of a line along the edge of the gingival margin
3점 = 치경부 1/3 부위에 치태가 있는 경우 3 points = there is a plaque in 1/3 of cervical area
4점 = 치관의 2/3 부위에 치태가 있는 경우 4 points = there is a plaque on 2/3 of the crown
5점 = 치관 전체를 거의 치태가 덮은 경우 5 points = Almost all teeth covered by the entire crown
PI = 총 점수의 합 / 검사한 총 치면수 PI = sum of total points / total number of teeth examined
<실험 결과><Experimental Results>
치태지수 측정결과를 하기 표 3에 나타내었다. 하기 표 3에 나타나는 바와 같이, 치약 사용 4주 후의 결과를 비교하면 비교예 1 치약 사용 후 초기대비 5.6% 증가하였고, 비교예 2 치약에서는 2.7% 감소하였고, 실시예 2 치약에서는 4.6% 감소하였다. 또한 연구대상자 중에서 치약 사용 4주 후 치태 지수가 치약 사용 전과 동일하거나 그보다 감소한 것으로 확인된 효과자율은 비교예 2 치약 사용자의 58%와 실시예 2 치약 사용자의 82%에 해당하는 것으로 확인되었다. 이를 통하여, 폴리크레줄렌 및 죽염을 함유한 구강용 조성물은 다양한 원인(예를 들어, 폴리크레줄렌의 구강 내에서의 흡착 증대)을 통하여 그 기능의 시너지적 증가를 가져옴을 알 수 있다.The results of the plaque index measurement are shown in Table 3 below. As shown in Table 3 below, the results after 4 weeks of using toothpaste showed a 5.6% increase compared to that of Comparative Example 1 toothpaste, a decrease of 2.7% in Comparative Example 2 toothpaste, and 4.6% in Example 2 toothpaste. In addition, it was confirmed that the effectiveness rate of the study subjects was found to be the same or lower than that of the toothpaste after 4 weeks of toothpaste use, that is, 58% of the toothpaste users of Comparative Example 2 and 82% of the users of the toothpaste of Example 2. Through this, it can be seen that oral compositions containing polycrysulene and bamboo salt cause a synergistic increase in their function through various causes (for example, increase in adsorption of polycrysulene in the oral cavity).
평균(표준편차)Baseline
Mean (standard deviation)
평균(표준편차)After 4 weeks
Mean (standard deviation)
실험예Experimental Example 3. 3. 폴리크레줄렌Polycrystalline 및 And 구강조직수렴제Oral tissue astringent agent 함유 치약의 소비자 평가 Consumer assessment of toothpaste
하기와 같은 방법으로 폴리크레줄렌 및 구강조직수렴제를 함유하는 치약의 소비자 관능 평가를 실시하였다.Consumer sensory evaluation of toothpaste containing polycrystalline and oral tissue astringent agent was carried out by the following method.
실험 대상자: 만 20-40대 성인 남녀 자원자 30명을 공개 모집하였다.Subjects: 30 volunteer men and women volunteers were recruited in the 20s and 40s.
실험방법: 실험 대상자들에게 1주일 주기로 새로운 치약을 지급하여 해당 치약만 사용하게 하면서, 설문조사를 통해 사용감에 대해 평가하게 하였다.Experimental method: The subjects were given a new toothpaste every week and were allowed to use only the toothpaste.
실험치약: 상기 표 1의 실시예 2 및 실시예 6 내지 11을 실험치약으로 지급하였다. 모든 조성물은 동일한 향료 및 색상을 적용하여 향료 및 색상에 의한 호불호는 사전에 방지하였다.Experimental toothpaste: Example 2 and Examples 6 to 11 in Table 1 were supplied as experimental toothpaste. All the compositions were applied with the same fragrance and color, and the fragrance and color were prevented in advance.
설문항목: 도 2에 나타난 바와 같은 소비자 평가용 설문지를 이용하여 평가하였다.Questionnaire items: Consumer evaluation questionnaire as shown in FIG. 2 was used for evaluation.
그 결과를 하기 도 3에 나타내었다. 도 3에 나타나는 바와 같이, 소비자 평가 결과는 실시예 2의 조성물이 세정감, 깔끔함의 지속, 향미 및 전반적인 만족도의 항목에서 가장 만족도가 높음을 알 수 있었다.The results are shown in Fig. As shown in FIG. 3, the consumer evaluation result shows that the composition of Example 2 is the most satisfactory in terms of the feelings of cleanliness, persistence of cleanliness, flavor and overall satisfaction.
실험예Experimental Example 4. 4. 폴리크레줄렌Polycrystalline 및 And 구강조직수렴제Oral tissue astringent agent 함유 치약의 항균력 평가 Evaluation of antibacterial activity of toothpaste containing
하기와 같은 방법으로 폴리크레줄렌 및 구강조직수렴제를 함유하는 치약의 소비자 관능 평가를 실시하였다.Consumer sensory evaluation of toothpaste containing polycrystalline and oral tissue astringent agent was carried out by the following method.
균주: Streptococcus mutans (ATCC 25175), Porphyromonas gingivalis (ATCC 49417), Prevotella nigrescens (ATCC 25261), Fusobacterium nucleatum (ATCC 25586)을 사용하였다. 균주는 Brain Heart Infusion (BHI: Difco, USA) 액체 배지에서 1~2차 계대 배양 후 같은 배지에 접종하여 37℃ 혐기성배양기 (Anaerobic incubator) 에서 72시간 배양 후 사용하였다. 배지는 BHI에 menadion(50ng/ml)과 hemin(4ug/ml)을 첨가하여 사용하였다.Strain: Streptococcus mutans (ATCC 25175), Porphyromonas gingivalis (ATCC 49417), Prevotella nigrescens (ATCC 25261), Fusobacterium nucleatum (ATCC 25586) was used. The strains were inoculated in the same medium and then incubated in an anaerobic incubator at 37 ° C for 72 hours after first and second subculture in a liquid medium of Brain Heart Infusion (BHI: Difco, USA). BHI was supplemented with menadion (50 ng / ml) and hemin (4 ug / ml).
실험방법: 상기 표 1의 실시예 2 및 실시예 6 내지 11을 BHI 액체배지에 희석하여 최종농도를 10%로 맞추고 3×105 CFU/ml의 세균과 함께 3분간 추가 배양하였다. 이 후 배양액을 순차적으로 희석하여 고체배지에 48시간 추가 배양하여 나타나는 CFU(Colony Forming Unit)를 조사하였다. 모든 실험군은 3회 반복 실험하였다.Experimental method: Example 2 and Examples 6 to 11 of Table 1 were diluted in a BHI liquid medium and the final concentration was adjusted to 10% and further cultured for 3 minutes with 3 × 10 5 CFU / ml of bacteria. After that, the cultures were sequentially diluted and cultured for 48 hours in a solid medium for CFU (Colony Forming Unit). All experiments were repeated three times.
그 결과를 하기 표 4에 나타내었다. 실험에 사용된 구강 내 미생물에 대한 항균력 비교 실험의 결과, 하기 표 4에 나타나는 바와 같이, 실시예 2의 조성물이 가장 항균력이 높음을 알 수 있었다.The results are shown in Table 4 below. As shown in Table 4, the composition of Example 2 showed the highest antibacterial activity against oral microorganisms used in the experiment.
Claims (9)
폴리크레줄렌의 효과를 높이기 위한 용도로 구강조직수렴제를 포함하는 것을 특징으로 하는 구강용 조성물.In an oral composition containing policresulen,
A composition for oral use characterized by containing an oral tissue astringent agent for enhancing the effect of polycrysulene.
(b) 상기 폴리크레줄렌의 효과를 높이기 위한 용도의 구강조직수렴제를 포함하는 조성물을
포함하는 구강용 키트.(a) a composition containing polycrystalline, and
(b) a composition comprising an oral tissue astringent agent for enhancing the effect of the polycrysulene
Included oral kit.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160140169A KR102649635B1 (en) | 2016-10-26 | 2016-10-26 | Oral composition comprising policresulen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160140169A KR102649635B1 (en) | 2016-10-26 | 2016-10-26 | Oral composition comprising policresulen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180045614A true KR20180045614A (en) | 2018-05-04 |
| KR102649635B1 KR102649635B1 (en) | 2024-03-19 |
Family
ID=62199921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160140169A Active KR102649635B1 (en) | 2016-10-26 | 2016-10-26 | Oral composition comprising policresulen |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102649635B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102077807B1 (en) * | 2018-08-29 | 2020-02-17 | 이향선 | Pharmaceutical composition for preventing or treating glioblastoma comprising pyrvinium and policresulen |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010069757A (en) | 2001-05-08 | 2001-07-25 | 류형선 | The new composition of taste masked policresulen solution |
| KR20040107974A (en) * | 2003-06-16 | 2004-12-23 | 한국디디에스제약 주식회사 | Oral applicator containing xylitol |
| KR20150066756A (en) | 2013-12-09 | 2015-06-17 | 주식회사 엘지생활건강 | Composition for preventing a biofilm formation |
-
2016
- 2016-10-26 KR KR1020160140169A patent/KR102649635B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010069757A (en) | 2001-05-08 | 2001-07-25 | 류형선 | The new composition of taste masked policresulen solution |
| KR20040107974A (en) * | 2003-06-16 | 2004-12-23 | 한국디디에스제약 주식회사 | Oral applicator containing xylitol |
| KR20150066756A (en) | 2013-12-09 | 2015-06-17 | 주식회사 엘지생활건강 | Composition for preventing a biofilm formation |
Non-Patent Citations (1)
| Title |
|---|
| J. of Korean Academy of Oral Health 2015 December 39(4):267-272, 1부.* * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102077807B1 (en) * | 2018-08-29 | 2020-02-17 | 이향선 | Pharmaceutical composition for preventing or treating glioblastoma comprising pyrvinium and policresulen |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102649635B1 (en) | 2024-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102548526B (en) | Dentifrice composition | |
| JP6471667B2 (en) | Liquid oral composition | |
| KR102735114B1 (en) | Oral composition for prevention or treatment of oral diseases | |
| KR20170037230A (en) | Oral composition comprising cassava extract | |
| KR20170103476A (en) | Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract | |
| KR20180045614A (en) | Oral composition comprising policresulen | |
| KR102597684B1 (en) | Oral composition comprising amaranth extract | |
| JP2014043441A (en) | Composition for oral cavity and candida biofilm formation inhibitor | |
| JPH06239723A (en) | Composition for oral cavity | |
| KR20170051006A (en) | Oral composition containing both isopropylmethylphenol and oral tissue astringent | |
| KR20160061852A (en) | Oral composition containing both metal chelating agent and isopropylmethylphenol | |
| JPH10167939A (en) | Oral composition | |
| KR101583758B1 (en) | Toothpaste composition comprising kiyoseki stone | |
| CA3050693A1 (en) | Oral care composition and use and method for the prevention and control of plaque formation, bad breath, gingivitis, periodontal diseases and/or dental caries | |
| KR102550067B1 (en) | Oral Composition having policresulen and fluorine compound | |
| KR20170037231A (en) | Oral composition comprising purslane extract | |
| KR102597685B1 (en) | Oral composition comprising parsley extract | |
| KR101818211B1 (en) | Composition for prevention or treatment of oral disease comprising Arctill fructus Extract | |
| KR20170120411A (en) | Composition for prevention or treatment of oral disease comprising Scopoletin | |
| JP2025035884A (en) | Composition for oral flora | |
| KR20170120399A (en) | Composition for prevention or treatment of oral disease comprising Genistein | |
| KR20170103494A (en) | Composition for prevention or treatment of oral disease comprising Melonis Pedicellus Extract | |
| KR101475594B1 (en) | Oral care composition comprising the borneolum and bamboo salt | |
| KR101583760B1 (en) | Toothpaste composition comprising chondrodite | |
| KR20130035323A (en) | Oral composition comprising saponin extracted from the root of camellia sinensis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20161026 |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210813 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20161026 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230614 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20231221 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20240315 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20240315 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |